<DOC>
	<DOCNO>NCT01895231</DOCNO>
	<brief_summary>The primary purpose study evaluate effect IV iron isomaltoside 1000 compare placebo Hb first-time female donor p-ferritin 30 µg/L</brief_summary>
	<brief_title>A Study Intravenous Iron Isomaltoside 1000 ( Monofer® ) Administered Infusions Iron-deficient Blood Donors</brief_title>
	<detailed_description>At present , clinical efficacy safety data available iron isomaltoside 1000 administer patient IDA require iron therapy . However , need clinical efficacy safety data within iron deficiency without anaemia e.g . observe blood donor . Thus , study plan compare efficacy safety parenteral iron isomaltoside 1000 placebo female blood donor p-ferritin 30 µg/L .</detailed_description>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Women age ≥ 18 year 2 . Firsttime donor 3 . Pferritin &lt; 30 µg/L 4 . Willingness participate sign informed consent form 1 . Iron overload disturbance utilisation iron ( e.g . haemochromatosis haemosiderosis ) 2 . Known hypersensitivity excipients investigational drug product 3 . History drug relate allergy 4 . History severe asthma 5 . Decompensated liver cirrhosis hepatitis ( define ALAT &gt; 3 time upper limit normal ) 6 . Active acute chronic infection ( assessed clinical judgement supply White Blood Cells ( WBC ) CReactive Protein ( CRP ) ) 7 . Rheumatoid arthritis symptom sign active inflammation 8 . Subjects pregnant nursing . In order avoid pregnancy , woman postmenopausal ( least 12 month since last menstruation ) , surgically sterile , use one follow contraceptive whole study period study end least 5 time plasma biological halflife investigational medicinal product : intrauterine device hormonal contraceptive ( contraceptive pill , implant , transdermal patch , vaginal device , hormonal injection prolong release ) 9 . Participation clinical study study drug pass 5 halflives prior screen 10 . Untreated vitamin B12 folate deficiency 11 . Treated IV oral iron product within 4 week prior screen 12 . Treated Erythropoietin ( EPO ) within 4 week prior screen 13 . Any medical condition , opinion Investigator , may cause subject unsuitable completion study place subject potential risk study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>